COMP <GO>
VRTX vs ABBV // ENTERPRISE SCALE & MARKET CAP
Vertex Pharmaceuticals Incorporated (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: VRTX 9
— ABBV 6
▲ ENTERPRISE SCALE & MARKET CAP LEADER: ABBV
LAST: $558.88 (+3.50%) • MKT CAP: $136.87B
market-cap
$136.87B
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
market-cap
$513.86B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VRTX VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VRTX | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 86.20% | 70.20% | +16.00 | VRTX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 20.00% | 29.00% | -9.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 29.6x | 33.3x | -3.70 | VRTX | /valuation <GO> |
| Free Cash Flow Yield | 2.33% | 3.47% | -1.14 | ABBV | /fcf-yield <GO> |
| Operating Margin | 34.80% | 24.60% | +10.20 | VRTX | /operating-margins <GO> |
| Net Profit Margin | 32.90% | 6.90% | +26.00 | VRTX | /net-margins <GO> |
| Revenue Growth (YoY) | 8.90% | 8.60% | +0.30 | VRTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 13.86 | 5.33 | +8.53 | VRTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | VRTX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.00% | 7.40% | -0.40 | VRTX | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 67.7 | 72.8 | -5.13 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.02 | 1.15 | -0.13 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 32.2x | 113.1x | -80.90 | VRTX | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $136.87B | $513.86B | -$376.99B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VRTX REV | ABBV REV | VRTX GROSS % | ABBV GROSS % | VRTX FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $12.00B | $61.16B | 86.2% | 70.2% | $3.19B | $17.82B |
| FY 2024 | $11.02B | $56.33B | 86.1% | 70.0% | -$790.3M | $17.83B |
| FY 2023 | $9.87B | $54.32B | 44.0% | 44.0% | $3.09B | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VRTX // BETA 1.02
ABBV // BETA 1.15